[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100414519":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":33,"responsibleParty":46,"collaborators":33,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":33,"enrollmentInfo":59,"targetDuration":33,"studyType":62,"phases":63,"briefSummary":66,"conditions":67,"keywords":33,"overallStatus":72,"whyStopped":33,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":33},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NAC PLUS SURGERY","EXPERIMENTAL","Patients receive three cycles of the modified dose of TGO plus oxaliplatin before curative gastrectomy.",[13],"Drug: Chemotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"SURGERY FIRST","ACTIVE_COMPARATOR","Patients undergo curative gastrectomy without any prior chemotherapy.",[19],"Procedure: Curative gastrectomy",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Chemotherapy","Modified SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 100mg\u002FM2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg\u002FM2 oral (twice daily) Repeated every 22nd day",[9],[27],"Modified SOX",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"PROCEDURE","Curative gastrectomy","Radical gastrectomy with D2 lymph node dissection",[15],null,[35],{"name":36,"affiliation":5,"role":37},"Zhenggang Zhu","STUDY_CHAIR",[39,45],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Birendra K Sah","CONTACT","0086-21-64370045","6701302","rjsurgeon@hotmail.com",{"name":36,"role":41,"phone":33,"phoneExt":33,"email":33},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"SPONSOR_INVESTIGATOR","BIRENDRA KUMAR SAH","Principal Investigator","100414519","phase-2-neoadjuvant-chemotherapy-plus-surgery-versus-surgery-first-for-elderly-gastric-cancer-patients-100414519",false,"NCT04677673","Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients","RJGC-Senile","Inclusion Criteria:\n\n* Histology confirmed non-obstructive adenocarcinoma of the stomach or esophagogastric junction.\n* Clinical stage: cTNM: stage III\n* Performance status: Eastern Cooperative Oncology Group ECOG ≤ 2 (normal to symptomatic but in bed less than half the day)\n* Clinically fit for systemic chemotherapy and gastric cancer surgery, i.e. adequate renal, hepatic, hematologic, and pulmonary function.\n* Written informed consent\n\nExclusion Criteria:\n\n* Clinically unfit for systemic chemotherapy and gastric cancer surgery, i.e. uncontrolled cardiac disease, or other clinically significant uncontrolled comorbidities, unable to undergo general anesthesia\n* Distant metastases (including retroperitoneal lymph node)\n* Locally advanced inoperable disease (Clinical assessment)\n* Relapse of gastric cancer\n* Malignant secondary disease\n* Prior chemo or radiotherapy\n* Inclusion in another clinical trial\n* Known contraindications or hypersensitivity for planned chemotherapy","ALL","76 Years",{"count":60,"type":61},232,"ESTIMATED","INTERVENTIONAL",[64,65],"PHASE2","PHASE3","The main purpose of this study is to compare the feasibility and efficacy of neoadjuvant chemotherapy (modified SOX) for elderly patients with locally advanced gastric cancer.",[68,69,70,71],"Gastric Cancer","Chemotherapy Effect","Elderly Patients","Surgery","NOT_YET_RECRUITING","2020-12-17",{"date":75,"type":76},"2020-12-21","ACTUAL",{"date":78,"type":61},"2021-01",{"date":80,"type":61},"2027-01",{"name":48,"class":6}]